00:43 , Jan 24, 2017 |  BC Extra  |  Financial News

Aslan approved for Taipei listing

Aslan Pharmaceuticals Ltd. (Singapore) said it has been approved to list on Taiwan's Taipei Exchange. Founded in 2010, Aslan aims to acquire rights to molecules from pharmas, develop the candidates in Asia through proof-of-concept, and...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Company News

Aslan, Nanyang Technological University deal

Aslan partnered with the university to research and develop Modybodies, which are stabilized heavy chain mAb fragments, against three targets of Aslan’s choice. Aslan said the fragments are designed for higher tissue penetration due to...
07:00 , Oct 13, 2016 |  BC Extra  |  Company News

Aslan, Nanyang in antibody fragment deal

Cancer company Aslan Pharmaceuticals Ltd. (Singapore) said it partnered with Nanyang Technological University to develop Modybodies, which are stabilized heavy chain mAb fragments, against three targets of Aslan's choice. Aslan said the fragments are designed...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Agency for Science, Technology and Research, Aslan deal

The Agency for Science, Technology and Research (A*STAR) granted Aslan worldwide rights to a preclinical antibody targeting macrophage stimulating 1 receptor c-Met-related tyrosine kinase ( MST1R ; RON; CD136 ). A*STAR will be responsible for...
07:00 , Sep 1, 2016 |  BC Extra  |  Company News

Aslan picks up preclinical A*STAR antibody

Aslan Pharmaceuticals Pte. Ltd. (Singapore) acquired worldwide rights from Singapore's Agency for Science, Technology and Research (A*STAR) to a preclinical antibody targeting macrophage stimulating 1 receptor c-Met-related tyrosine kinase ( MST1R ; RON; CD136 )....
07:00 , Aug 15, 2016 |  BioCentury  |  Finance

Lion's share of the work

Aslan Pharmaceuticals Pte. Ltd .'s 2011 deal with Bristol-Myers Squibb Co. (NYSE:BMY) was atypical in terms of stage and scope, but the biotech thinks the partnership validates its business model of in-licensing cancer compounds, doing...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Company News

Bristol-Myers, Aslan deal

Aslan said Bristol-Myers reacquired rights to develop and commercialize cancer compound ASLAN002 ( BMS-777607 ) in China, Australia, Korea, Taiwan and other Asian territories. Aslan is to receive $10 million up front and is eligible...
07:00 , Aug 10, 2016 |  BC Extra  |  Company News

BMS reacquires rights to ASLAN002 from Aslan

Aslan Pharmaceuticals Pte. Ltd. (Singapore) said Bristol-Myers Squibb Co. (NYSE:BMY) reacquired rights to develop and commercialize cancer compound ASLAN002 ( BMS-777607 ) in China, Australia, Korea, Taiwan and other Asian territories. Aslan is to receive...
07:00 , Mar 31, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Macrophage stimulating 1 receptor c-Met-related tyrosine kinase (MST1R; RON; CD136) as a risk marker for nasopharyngeal cancer

Biomarkers TECHNOLOGY: SNPs Variants in MST1R could help predict the risk of nasopharyngeal cancer. Whole-exome sequencing in 161 nasopharyngeal cancer patients and 895 controls identified five heterozygous missense mutations in MST1R that were associated with...
01:31 , Jul 17, 2015 |  BC Extra  |  Company News

Aslan, NCCS to study GI cancers

Aslan Pharmaceuticals Pte. Ltd. (Singapore) and the National Cancer Centre Singapore signed a memorandum of understanding to jointly study gastrointestinal cancers that are disproportionately prevalent in Asia. Aslan and NCCS plan to study gastric cancer,...